| Company/Division name | Sterling Pharma Solutions |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2020 |
| Domestically, the work will be done: | In-house |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Germantown |
| State(s) reshored to: | WI |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | API, Active Pharmaceutical Ingredients |
| What domestic positive factors made reshoring more attractive? | Lead time/Time to market, Proximity to customers/market, Skilled workforce availability/training |
